Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.11 -1.36%

-$0.06 today

Market cap
$217.99M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.57M

Average 0.49M

BCYC Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Bicycle Therapeutics plcNASDAQ: BCYC

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$960.58M, compared with -$741.55M a year earlier.

Context

  • Retained earnings amounted to 147.2% of total assets at the end of Q1 FY2026, up 63.3 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -29.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$960.58M-6.8% QoQ
Last fiscal yearDec 2025
-$899.75M-32.2% YoY
Year agoMar 2025
-$741.55M-29.5% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.5%——
1 year-32.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(899.75M) USD
Year-over-year change
-32.2%

Retained Earnings vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's Mar 2026 retained earnings of -$960.58M is the 6th highest of the 10 companies compared; the peer median is -$857.64M.
  • Its year-over-year change of -29.5% is the lowest of 9, against a peer median of -13.6%.
  • Retained earnings amounts to 147.2% of total assets for BCYC, versus a peer median of 299.7%.
BCYC Competitors Peer median
Retained Earnings for BCYC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CMPXCompass Therapeutics, Inc.Mar 2026-$449.49M -17.9%—219.1%
FULCFulcrum Therapeutics, Inc.Mar 2026-$613.17M -14.2%—176.8%
KALVKalVista Pharmaceuticals, Inc.Dec 2025-$762.69M ——227.4%
FDMT4D Molecular Therapeutics, Inc.Mar 2026-$785.06M -25.8%—153.1%
OMEROmeros CorporationMar 2026-$857.64M +9.1%—299.7%
BCYCBicycle Therapeutics plcMar 2026-$960.58M -29.5%—147.2%
NMRANeumora Therapeutics, Inc. Common StockMar 2026-$1.24B -21.9%—804.3%
PRTAProthena Corporation plcMar 2026-$1.31B -13.0%—375.5%
ADCTADC Therapeutics S.A.Mar 2026-$1.67B -8.9%—572.5%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026-$2.02B -1.3%—750.9%
Peer median (excluding BCYC) -$857.64M-13.6%—299.7%

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents438.68M339.15M526.42M879.52M628.11M
Short-term Investments00000
Net Receivables11.91M21.21M24.04M35.65M35.59M
Inventory00000
Other Current Assets7.97M9.02M11.41M13.43M(35.59M)
Total Current Assets458.56M369.38M561.87M928.61M628.11M
Property, Plant & Equipment (Net)17.79M32.77M27.68M17.19M21.91M
Goodwill00000
Intangible Assets00000
Long-term Investments00547K547K58K
Tax Assets00000
Other Non-current Assets3.45M8.46M5.24M10.53M12.75M
Total Non-current Assets21.24M41.23M33.48M28.26M34.71M
Total Assets479.79M410.61M595.34M956.87M717.6M
Account Payables2.72M6.47M13.05M15.79M9.67M
Short-term Debt004.88M02.76M
Tax Payables00000
Deferred Revenue19.27M20.42M24.98M10.19M2.96M
Other Current Liabilities7M13.4M13.24M16.57M17.14M
Total Current Liabilities36.24M53.34M69.54M67.23M56.98M
Long-term Debt29.87M30.32M30.7M00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)52.07M41.46M110.22M91.47M35.51M
Other Non-current Liabilities3.28M3.83M4.58M1.12M363K
Total Non-current Liabilities97.3M86.48M154.88M96.58M50.64M
Total Liabilities133.54M139.83M224.41M163.81M107.62M
Common Stock384K387K550K890K894K
Retained Earnings(218.38M)(331.1M)(511.76M)(680.79M)(899.75M)
Accumulated OCI(3.39M)387K(1.3M)119K(3.51M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity346.25M270.78M370.93M793.06M609.98M
Total Debt44.34M44.33M44.96M9.49M17.52M
Net Debt(394.34M)(294.83M)(481.47M)(870.03M)(610.59M)

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.